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Cell lines are important models for drug resistance in acute lymphoblastic leukaemia (ALL), but are often criticised as being
unrepresentative of primary disease. There are also doubts regarding the authenticity of many lines. We have characterised a panel of
ALL cell lines for growth and drug resistance and compared data with that published for primary patient specimens. In contrast to the
convention that cell lines are highly proliferative, those established in our laboratory grow at rates similar to estimates of leukaemic
cells in vivo (doubling time 53–442h). Authenticity was confirmed by genetic fingerprinting, which also demonstrated the potential
stability of long-term cultures. In vitro glucocorticoid resistance correlated well with that measured ex vivo, but all lines were
significantly more sensitive to vincristine than primary specimens. Sensitivity to methotrexate was inversely correlated to that
of glucocorticoids and L-asparaginase, indicating possible reciprocity in resistance mechanisms. A cell line identified as highly
methotrexate resistant (IC50 48000-fold higher than other lines) was derived from a patient receiving escalating doses of the drug,
indicating in vivo selection of resistance as a cause of relapse. Many of these lines are suitable as models to study naturally occurring
resistance phenotypes in paediatric ALL.
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In children with acute lymphoblastic leukaemia (ALL) cellular
drug sensitivity is a major component of clinical outcome. This is
true not only for relapsed ALL (Klumper et al, 1995) where in vivo
selection of resistant clones occurs during therapy, but also in
those newly diagnosed with the disease (Kaspers et al, 1997; Pieters
et al, 1998). Much of our knowledge of the resistance phenotypes
in ALL has been derived using isolated bone marrow specimens
studied in short-term culture using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. However,
application of this ex vivo approach for functional studies or drug
screening is limited by both the availability of patient material and
the short period of survival of these cells in culture. Furthermore,
this approach cannot be used to measure methotrexate (MTX)
resistance in such specimens because the high rate of spontaneous
cell death releases nucleosides in sufficient quantity to prevent
MTX cytotoxicity (Pieters et al, 1997). Investigation of resistance
mechanisms and evaluation of novel drug-leads invariably requires
the use of immortalised cell lines, but the extent to which these
cells retain features of the original disease in vivo is a matter of
some debate (Kamb, 2005), a problem exemplified by the typically
high growth rates of continuous cultures (Masters, 2000). Added to
this is concern over the alarming frequency with which cultures
have been found retrospectively to be infected with mycoplasma or
cross-contaminated with other cell lines (so-called ‘false’ lines)
(Masters, 2000; Drexler et al, 2003). This has led to repeated calls
for the extensive characterisation and validation of authenticity of
such cell lines (Drexler and Matsuo, 1999; Masters et al, 2001;
Drexler et al, 2002, 2003).
Over the past 20 years our laboratory has developed a panel
of paediatric ALL cell lines that have been grown in the absence
of drug selection. Previously, we have shown, using a subset of
this panel, that these cultures retain critical immunophenotypic
and molecular features of the primary disease (Kees et al, 2003).
Here, we have validated the genetic identity of these lines and have
systematically studied their drug resistance and growth profiles to
assess the degree to which they reflect the phenotype of primary
ALL patient specimens.
MATERIALS AND METHODS
Cell lines
PER cell lines were derived from paediatric ALL bone marrow
specimens as described previously (Kees et al, 1987). Patients were
diagnosed and treated at the Princess Margaret Hospital for
Children, Perth, Western Australia, and informed consent was
obtained from parents, patients, or both as deemed appropriate.
Several of the cell lines have been described previously (Kees, 1987;
Kees et al, 1987, 1989a,b, 1990, 1995, 2003; Kennedy et al, 1991;
Received 27 June 2006; revised 20 September 2006; accepted 26
September 2006; published online 21 November 2006
*Correspondence: Professor UR Kees; E-mail: ursula@ichr.uwa.edu.au
4AHB and MLP share equal first authorship
British Journal of Cancer (2006) 95, 1537–1544
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sWhitman et al, 2001). CCRF-HSB2 (HSB2) cells were obtained
from the American Type Culture Collection; CCRF-CEM (CEM)
from the Children’s Cancer Institute Australia for Medical
Research, Sydney; JURKAT from the Basel Institute for Immuno-
logy, Switzerland; ALL-SIL from MRC Laboratory of Molecular
Biology, Cambridge, UK; MOLT4 from the German Cancer
Research Center, Heidelberg, Germany; DU.528 from the Division
of Cancer Biology, Telethon Institute for Child Health Research,
Perth. Cell lines were grown in RPMI-1640 supplemented with
2m ML -glutamine, 10nM 2-mercaptoethanol and 10–20% heat-
inactivated foetal calf serum. All PER cell line media contained
additional non-essential amino acids and pyruvate, whereas 300U/
ml interleukin-2 is required for growth of PER-427 and PER-487
(Kees et al, 2003). Cell lines were cultured in the absence of
antibiotics; testing for mycoplasma was routinely performed by
PCR, and immunophenotyping performed by indirect immuno-
fluorescence and flow cytometry (Kees et al, 1987, 2003). Doubling
times were determined using the MTT assay (described below) and
extensive laboratory records. DNA fingerprinting of matched cell
lines and patient specimens was performed by Genetic Techno-
logies Corporation Pty Ltd (Melbourne, Australia) using the
AmpF/short tandem repeat (STR) Identifiler kit which co-amplifies
15 STR loci and the sex determination locus Amelogenin. Allelic
profiles were assessed by calculating the percentage of alleles at
the 16 loci present in cell lines that were also co-identified in the
corresponding patient specimen (Supplementary Table 1).
In vitro drug resistance
Resistance was tested using the MTT assay (Alley et al, 1988). Cells
in exponential growth phase were counted by trypan blue
exclusion and seeded in fresh media at a density of 5 10
5–
1.5 10
6cellsml
 1 in a 96-well plate in the presence or absence of
each drug. Drugs were serially diluted in fresh media, with each
drug concentration tested in triplicate. Culture plates were
incubated for 4 days at 371C before the addition of 10ml
of filter-sterilised MTT (5mgml
 1). Plates were re-incubated for
6h before addition of 100ml of acidified isopropyl alcohol solution
to dissolve formazan crystals and measurement of absorbance at
590nm. Testing was performed using two-fold step dilutions of the
following drug ranges: cytosine arabinoside (ARA-C; Pharmacia
Pty Ltd, NSW, Australia) 0.3pgml
 1–2.5mgml
 1; dexamethasone
(DEX; Mayne Pharma Pty Ltd, VIC, Australia) 30pgml
 1–
250mgml
 1; methylprednisolone (MPRED; David Bull Labora-
tories, VIC, Australia) 30pgml
 1–250mgml
 1; 6-thioguanine
(6TG; GlaxoSmithKline Australia Pty Ltd, VIC, Australia)
12pgml
 1–100mgml
 1; 6-mercaptopurine (6MP; GlaxoSmith-
Kline) 60pgml
 1–500mgml
 1; daunorubicin (DNR; Pharmacia)
0.2pgml
 1–2mgml
 1; doxorubicin (DOX; Mayne Pharma Pty Ltd)
1pgml
 1–8mgml
 1; L-asparaginase (ASP; Kyowa Hakko Kogyo
Co. Ltd, Tokyo) 2.4 10
 6–20IUml
 1; vincristine (VCR;
Pharmacia) 23fgml
 1–195ngml
 1; methotrexate (MTX; David
Bull Laboratories) 60pgml
 1–500mgml
 1. The IC50 (drug concen-
tration that inhibits cell growth by 50%) was used as the measure
of drug resistance. Data represent the average of 2–6 separate
experiments and linearity was checked between viable cell number
and optical density for each cell line. Where 50% cytotoxicity
was not achieved by even the highest dose, the IC50 was recorded
as double the highest concentration tested.
Comparison of in vitro and ex vivo resistance profiles
Data from multiple studies (Pieters et al, 1990, 1991, 1998;
Klumper et al, 1995; Duyn et al, 1999; Styczynski et al, 2000, 2002,
2005; Zwaan et al, 2000; Mihal et al, 2004; Fine et al, 2005; Kaspers
et al, 2005; Steinbach et al, 2005) were combined to determine an
absolute minimum and maximum IC50 range for bone marrow
specimens obtained from paediatric ALL patients at the time of
diagnosis (PD) or relapse (PR). Data reported in these studies as
LC50 values are, for simplicity, referred to here in terms of IC50.
Eligible studies satisfied the following criteria: (i) drug sensitivity
was tested in primary ALL specimens using the MTT assay; (ii)
drug incubation was for 3–5 days with no exposure to other agents
before testing; (iii) resistance was reported using IC50 or LC50
values; (iv) patients were under 19 years of age and were divided
into diagnosis and relapse cohorts. In the two cases where patients
were stratified by immunophenotype (Pieters et al, 1998; Kaspers
et al, 2005), data from T- and B-lineage specimens were combined
before analysis. Data for MPRED were available from only one
study (Styczynski et al, 2002), Whilst MTX sensitivity cannot be
measured in primary specimens using the MTT assay (Pieters et al,
1997).
Statistical analysis
All comparisons were performed on Log2 IC50 data; the Epstein–
Barr virus (EBV)-transformed cell line PER-607 was not included
in any of the analyses. Significant differences in IC50 values
between drugs (in molarity) were determined using the non-
parametric Wilcoxon-matched pairs signed ranks test. All other
differences were assessed using the Mann–Whitney U-test.
Spearman’s correlations were used to assess relationships between
drug profiles (IC50 values). Delta IC50 profiles for MPRED, DEX,
ASP and MTX were calculated by subtracting median Log2 IC50
values (T-ALL cell lines, n¼15) from the Log2 IC50 score for each
cell line.
RESULTS
Characterisation of cell lines
The 17 cell lines developed in our laboratory are listed in Table 1.
The panel comprises nine T-ALL and seven B-lineage ALL lines
derived from children at different stages of disease (diagnosis or
relapse), and one EBV-transformed cell line (PER-607) which was
originally derived from the diagnostic specimen of a patient that
expressed both T- and B-cell markers. The cell line demonstrated
a B-lineage immunophenotype and the presence of EBV was
confirmed by PCR. DNA fingerprinting verified the genetic
identity of the cell lines, with 13 out of 17 lines showing 100%
allelic concordance with original patient specimens across 16
genomic loci (Table 1 and Supplementary Table 1). The minor
allelic variations we observed in four lines (88–97% concordant)
are consistent with the genetic drift associated with cancer cells
grown in culture over extended periods (Masters et al, 2001). The
primary patient specimen for PER-117 demonstrated additional
(tertiary) alleles in low abundance at several loci (6 out of 16 loci),
which were not present in the DNA from PER-117 (Supplementary
Table 1). This specimen was obtained from a patient who relapsed
2 months after receiving a bone marrow transplant from his
brother; the minor alleles are indicative of the presence of residual
donor cells in the marrow aspirate at relapse.
Cell line drug resistance profiles
The cell lines in Table 1 and six additional T-ALL cell lines
obtained from external sources, were tested for their sensitivity to
the 10 drugs most commonly used in the treatment of paediatric
ALL. The IC50 values for each cell line are listed in Table 2 along
with their doubling time for growth in culture. The experimental
protocol (i.e. measurement by MTT assay after a 4-day drug
incubation) was modelled on the approach successfully used to
assess drug resistance in primary ALL bone marrow specimens ex
vivo (Klumper et al, 1995; Kaspers et al, 1997, 2005). For most
drugs, sensitivities ranged over several orders of magnitude. The
EBV-transformed cell line PER-607 had relatively high IC50 values
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sfor most of the drugs tested, although these were still within the
range demonstrated for ALL lines. Although included here for
general interest, the drug resistance profile of this cell line was
not included in subsequent analyses.
The resistance profiles of the 15 T-ALL and seven B-lineage ALL
cell lines are shown graphically in Figure 1. Among T-ALL lines
(open boxes), greatest resistance was to the steroids (DEX and
MPRED) and thiopurines (6MP and 6TG) with median IC50 values
several orders of magnitude higher than the other drugs; greatest
sensitivity was to VCR and ASP. A similar drug profile was
observed in the B-lineage cell lines (Figure 1, shaded boxes). The
parental CCRF-CEM cell line is known to represent a mixed
population of sensitive and resistant clones (Medh et al, 2003); IC50
values for DEX and ASP for this cell line (Table 2) were much
higher than have been reported elsewhere (Martin-Aragon et al,
2000; Catts et al, 2001; van der Heijden et al, 2004), indicating that
our CEM represents a resistant sub-clone that has grown out
during culture.
Although there were considerable differences in medians
between the T- and B-lineage ALL cell lines for some drugs,
particularly DEX and ASP, these did not reach statistical
significance owing to the considerable variation observed within
each lineage (Mann–Whitney U-test, P40.05). Previous work
in primary specimens has indicated that T-ALL specimens are
more resistant than precursor B-lineage to several front-line drugs,
especially ASP, VCR and glucocorticoids (Pieters et al, 1998).
Although the trend for DEX in our data is in agreement with
these findings, for the other drugs, particularly ASP, this is
not the case. Larger in vitro studies are required to confirm these
findings.
Daunorubicin was approximately three times more potent than
DOX in both lineages (Wilcoxon-matched pairs test: T-ALL,
Po0.001; B-lineage ALL, P¼0.018; T and B lineages combined,
Po0.0001), whereas 6TG was 6–24 times more cytotoxic than 6MP
(Wilcoxon-matched pairs test: T-ALL, Po0.005; B-lineage ALL,
Po0.05; T and B lineages combined, Po0.0005). These obser-
vations are consistent with previous reports of the in vitro
cytotoxicity of these agents (Adamson et al, 1994; Klumper et al,
1995; Pieters et al, 1998; Kaspers et al, 2005). No significant
differences in cytotoxicity were observed between DEX and
MPRED (P40.05).
An increase in resistance to many front-line drugs, particularly
the glucocorticoids, has been reported at the time of ALL relapse
(Klumper et al, 1995; Rots et al, 2000), the phenomenon being
most pronounced in those with pre-B-ALL (Kaspers et al, 2005). In
the present study, there was no significant difference in drug
sensitivity between cell lines derived from diagnosis or relapse
specimens, but there was a trend towards increased steroid
resistance in B-ALL lines derived from relapse patient (Table 1).
Comparison of in vitro and in vivo drug resistance
To assess how the spectrum of drug resistance observed in the cell
line panel related to levels of resistance found in patients, we
compared our data with that published from ex vivo studies of
primary paediatric ALL specimens. The studies included in this
analysis are shown in Table 3 and were selected using strict criteria
for experimental design, both to minimise variations caused by
laboratory handling and to facilitate comparison with data
obtained in the present study (see Materials and Methods). As
most of the published data were not stratified for immunopheno-
type, data for T- and B-lineage cell lines were combined for this
analysis. The data are compared with cell line resistance profiles in
Figure 2, with the medians from the multiple studies indicated
by individual tick marks. Studies of primary ALL specimens have
consistently indicated an increase in median glucocorticoid
resistance at relapse (Figure 2, PR), yet some patients are highly
resistant to these agents even at the time of first diagnosis
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s(Figure 2, PD), with the maximum reported range for DEX being
similar in both cases. For the other compounds in Figure 2,
diagnosis and relapse resistance profiles overlap significantly
reiterating the particular importance of steroid resistance in
relapsing patients. Among the cell lines (CLD/CLR), some were
particularly resistant to DEX, exceeding LC50 values reported for
even the most resistant relapse patient (Figure 2 and Table 2).
However, the highest dose tested in the patient studies was
6mgml
 1, many times lower than the maximum dose used in the
present study (250mgml
 1) and so the reported LC50 range for
patients at relapse is likely to be an underestimate.
All cell lines, without exception, were significantly more
sensitive to VCR than patient specimens. Lines were also more
sensitive to ASP, 6MP and DOX than primary specimens
(primarily owing to lower values in T-ALL cell lines, see Figure 1),
although these differences were not as extreme. Data for MTX
resistance measured using the MTT assay in primary specimens
are not available. Methotrexate sensitivities have been successfully
compared in primary specimens using in situ inhibition of
thymidylate synthetase (Rots et al, 2000), but the data are not
comparable to the growth inhibition studies performed in the
present study. However, peak plasma concentrations after a
20mgm
 2 oral dose range from 0.1 to 1.4mgml
 1 (Balis et al,
1998), and in comparison to this, all cell lines with the exception of
PER-145 were relatively sensitive (Table 2). PER-145 was extra-
ordinarily resistant to MTX, having an IC50 48000 times higher
than even the next most resistant cell line.
Cross-resistance between drugs
Spearman’s correlations were used to identify drugs with similar
profiles across the T-ALL cell line panel, which represents a larger
and more homogenous group than the B-lineage cell lines. IC50
scores for drugs with a similar mechanism of action (Table 4,
boxed) were highly correlated to each other (DEX vs MPRED, DNR
vs DOX and 6MP vs 6TG, all Po0.001), demonstrating that this is a
valid approach for the identification of potential cross-resistance
between compounds, although it should be emphasised that these
relationships were not directly tested in the present study. DEX
showed significant correlation (bold values, Po0.05) to all drugs,
except MTX and the thiopurines; MPRED mirrored this pattern,
particularly in regard to ASP, DNR and MTX, the latter showing an
inverse relationship as it did with DEX. The relationship between
MPRED, DEX, ASP and MTX in the T-ALL cell lines is
demonstrated graphically in Figure 3, which displays the resistance
spectrum of the panel for each of the four drugs. The Delta IC50
score used in this analysis essentially ranks the cell lines for their
resistance in comparison to the population median (positive scores
Table 2 Growth and drug resistance profile of ALL cell lines
Cell line Phenotype Specimen DT (h) ARA-C 6MP 6TG MTX DEX MPRED DNR DOX ASP VCR
ALL-SIL T-ALL Relapse 64 0.0303 0.416 0.652 0.00649 11.620 137.31 0.00933 0.09500 0.00007 0.00020
CEM T-ALL Relapse 23 0.0939 1.240 0.613 0.00599 500 419.88 0.20400 0.42900 1.99695 0.00213
DU528 T-ALL Diagnosis 40 0.0123 65.800 1.845 0.0101 500 190.16 0.05300 0.18800 0.00003 0.00308
HSB2 T-ALL Diagnosis 40 0.0020 0.283 0.141 0.0055 2 276.98 0.00092 0.00072 0.04390 0.00013
JURKAT T-ALL Relapse 26 0.0153 0.410 0.334 0.00784 500 500 0.01400 0.03270 1.25424 0.00168
MOLT4 T-ALL Relapse 33 0.0129 0.454 0.348 0.00671 500 356.04 0.00319 0.01360 0.09690 0.00078
PER-117 T-ALL Relapse 56 0.0059 0.042 0.049 0.00539 32.440 85.71 0.00435 0.01100 0.03022 0.00022
PER-255 T-ALL Diagnosis 66 0.0033 0.223 0.060 0.00683 0.003 0.05 0.00163 0.00475 0.00004 0.00016
PER-427 T-ALL Diagnosis 209 0.2810 22.500 50.800 0.00702 51.990 0.19 0.01110 0.05460 0.43701 0.00493
PER-487 T-ALL Diagnosis 363 0.0264 15.100 3.175 0.0111 189.080 14.45 0.01060 0.05410 0.00008 0.00141
PER-537 T-ALL Diagnosis 223 0.0172 22 1.072 0.0339 167.020 9.86 0.00325 0.01340 0.00016 0.00036
PER-550 T-ALL Relapse 252 0.0030 3.550 0.440 0.0333 0.002 0.02 0.00163 0.00956 0.00003 0.00025
PER-604 T-ALL Relapse 181 0.0059 16 1.572 0.0866 0.117 0.17 0.00428 0.03610 0.00003 0.00080
PER-606 T-ALL Relapse 442 0.0008 8.460 0.758 0.0678 0.001 0.02 0.00216 0.00762 0.00003 0.00017
PER-608 T-ALL Diagnosis 260 0.0073 6.670 0.142 0.0123 0.003 0.06 0.00128 0.00405 0.00004 0.00033
Median 0.0123 3.550 0.613 0.0078 32.440 14.45 0.00430 0.01360 0.00010 0.00040
PER-145 Pre-B-ALL Relapse 108 0.0572 173.965 10.940 725.1374 500 84.75 0.04880 0.05436 0.00007 0.00161
PER-278 Pre-B-ALL Diagnosis 104 0.0073 47.754 1.795 0.00929 0.072 1.08 0.00245 0.00904 0.28644 0.00080
PER-371 Pre-B-ALL Diagnosis 69 0.0040 39.708 71.600 0.01466 0.003 0.06 0.00600 0.01174 0.95612 0.00089
PER-377 B-ALL Relapse 66 0.0211 0.829 0.360 0.00546 0.0329 26.13 0.01230 0.08807 1.20029 0.01150
PER-490 Infant Pre-B-ALL Diagnosis 97 0.0279 97.495 3.200 0.00602 0.002 0.01 0.00669 0.02071 0.00003 0.00073
PER-495 B-ALL Relapse 53 0.0034 0.080 0.037 0.00637 304.170 180.12 0.00419 0.01045 0.01631 0.00059
PER-485 Infant Pre-B-ALL Relapse 53 2.5000 0.321 0.338 0.00245 500 500 0.00358 0.15423 0.19488 0.00030
Median 0.0211 39.7077 1.7950 0.0064 0.0719 26.1250 0.0060 0.0207 0.1949 0.0008
PER-607 EBV Diagnosis 216 0.9992 62.198 13.580 0.01312 307 301.46 0.01110 0.07281 0.31872 0.00230
ALL¼acute lymphoblastic leukaemia; ARA-C¼cytosine arabinoside; ASP¼ L-asparaginase; DEX¼dexamethasone; DNR¼daunorubicin; DOX¼doxorubicin; DT¼doubling
time; EBV¼Epstein–Barr virus-transformed cell line; 6MP¼6-mercaptopurine; MTX¼methotrexate; 6TG¼6-thioguanine; MPRED¼methylprednisolone; VCR¼vincristine.
IC50 units are mgml
 1, except for ASP (IUml
 1).
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Figure 1 Drug resistance profile of ALL cell lines. IC50 values for T-ALL
(open, n¼15) vs B-lineage ALL (shaded, n¼7) cell lines. Boxes indicate
medians and inter-quartile range, whiskers indicate 10th and 90th
percentiles and dots indicate outliers; values are calculated as log2molarity
(mM) for all drugs, except ASP which is given as log2 IUml
 1.
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sTable 3 Details of ex vivo resistance studies used for comparison with in vitro data
Drug No. of studies
No. of diagnosis
specimens
No. of relapse
specimens
Total No. of
specimens References
DEX 7 737 248 985 1, 2, 5, 8, 9, 11, 13
MPRED 1 13 6 19 9
VCR 9 1137 275 1412 1, 2, 5–8, 11–13
ARA-C 9 995 331 1326 1–3, 5, 8, 10–13
6MP 5 764 220 984 1, 2, 5, 8, 11
6TG 9 973 291 1264 1–3, 5, 7, 8, 11–13
DNR 8 1126 278 1404 1, 2, 5, 7, 8, 11–13
DOX 5 580 257 837 1, 2, 5, 8, 11
ASP 7 1013 275 1288 1, 2, 4, 5, 8, 11–12
ARA-C¼cytosine arabinoside; ASP¼ L-asparaginase; DEX¼dexamethasone; DNR¼daunorubicin; DOX¼doxorubicin; 6MP¼6-mercaptopurine; 6TG¼6-thioguanine;
MPRED¼methylprednisolone; VCR¼vincristine. References: (1) Klumper et al (1995); (2) Pieters et al (1998); (3) Duyn et al (1999); (4) Fine et al (2005); (5) Kaspers et al
(2005); (6) Mihal et al (2004); (7) Pieters et al (1991); (8) Styczynski et al (2000); (9) Styczynski et al (2002); (10) Styczynski et al (2005); (11) Zwaan et al (2000); (12) Pieters
et al (1990); (13) Steinbach et al (2005).
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Figure 2 Comparison of resistance profiles in patients and cell lines. Data indicate total IC50 ranges determined from published studies of diagnosis (PD)
and relapse (PR) patient specimens, and from cell lines derived from diagnosis (CLD) and relapse (CLR) specimens in the present study. Median values from
individual studies are indicated as tick marks. Median values from the single study of MPRED resistance in patient specimens are indicated as crosses. Data
represent combined T and B lineages; values are mgml
 1 for all drugs, except ASP which is given as IUml
 1.
Table 4 Cross-correlation of drug-resistance (IC50) profiles in 15 T-ALL cell lines
DEX MPRED ASP MTX DNR DOX VCR ARAC 6TG 6MP
DEX — 0.85 0.59  0.35 0.74 0.67 0.71 0.70 0.24 0.14
MPRED 0.85 — 0.68  0.62 0.54 0.46 0.37 0.48  0.11  0.26
ASP 0.59 0.68 —  0.59 0.34 0.21 0.29 0.57  0.17  0.32
MTX  0.35  0.62  0.59 —  0.17  0.09 0.15  0.23 0.51 0.68
DNR 0.74 0.54 0.34  0.17 — 0.91 0.78 0.73 0.50 0.29
DOX 0.67 0.46 0.21  0.09 0.91 — 0.76 0.77 0.65 0.42
VCR 0.71 0.37 0.29 0.15 0.78 0.76 — 0.69 0.63 0.61
ARA-C 0.70 0.48 0.57  0.23 0.73 0.77 0.69 — 0.46 0.28
6TG 0.24  0.11  0.17 0.51 0.50 0.65 0.63 0.46 — 0.89
6MP 0.14  0.26  0.32 0.68 0.29 0.42 0.61 0.28 0.89 —
ALL¼acute lymphoblastic leukaemia; ARA-C¼cytosine arabinoside; ASP¼ L-asparaginase; DEX¼dexamethasone; DNR¼daunorubicin; DOX¼doxorubicin; 6MP¼6-
mercaptopurine; MTX¼methotrexate; 6TG¼6-thioguanine; MPRED¼methylprednisolone; VCR¼vincristine. Boxes indicate drugs paired by compound class; Bold entries,
Po0.05.
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smore resistant than the median, negative scores more sensitive
than the median). Cell lines resistant to MPRED, DEX and ASP
were generally the most sensitive to MTX and vice versa (Po0.05
for negative correlation between MTX and ASP, Table 4). Resis-
tance profiles to the anthracyclines (DNR and DOX), ARA-C and
VCR were all significantly correlated to each other in T-ALL cell
lines (Table 4, all Pp0.005), indicating cross-resistance.
DISCUSSION
A frequent criticism of cancer cell lines is that they are
unrepresentative of the primary disease as they originate from
highly proliferative cell populations that are particularly amenable
for growth in culture (Masters, 2000). This is exemplified by the
six cell lines included in this study that were obtained from
external sources, all of which grow quickly and are easy to
maintain (Table 2). In contrast, many of our own cell lines are
slow growing and were extremely difficult to establish. Notably,
our panel represents an unselected cohort of patients, with half of
the lines originating from diagnostic specimens. The doubling time
of non-leukaemic pre-B cells measured ex vivo is B65–90h,
whereas leukaemic pre-B cells are thought to be more hetero-
geneous, ranging from 25 to 240h (Hirt et al, 1992; Cooperman
et al, 2004); primary leukaemic T-ALL cells have a similar growth
profile (Hirt et al, 1992). The wide range of growth rates among the
cell line panel (23–442h, Table 2) mirrors these reported values,
indicating that they may be closer to the in vivo situation than
is commonly believed for such cell lines. In accordance with
published guidelines (Drexler and Matsuo, 1999; Drexler et al,
2003), we have validated the authenticity of these cell lines by
genetic fingerprinting. Despite the fact that some were isolated up
to 20 years ago, there was an impressive degree of concordance
with the primary specimens from which they were derived,
indicating a high degree of stability in long-term routine culture.
In this study, we have not directly tested the drug resistance
profiles of the patient specimens from which our cell lines were
derived. However, comparison with previously published data
indicates that for each of the drugs tested here, except VCR, there
are several cell lines within the panel that accurately reflect the
sensitivity of leukaemic blasts tested ex vivo; for DEX, ARA-C, 6TG
and DNR, the overlap between in vitro and ex vivo data is
particularly strong. The lines included in this study have always
been maintained without selection pressure (i.e. are grown without
antibiotics and have had no drug exposure before MTT testing)
and thus represent an ideal model system for the investigation of
resistance mechanisms that may occur naturally in vivo; to this
end, experiments are underway to examine the gene-expression
profile of the panel by high-density oligonucleotide microarray.
However, the consistent hypersensitivity of all cell lines to VCR
may be an indication that in vitro studies of resistance for this
drug should be interpreted with caution. The observation cannot
be explained as an artefact of high proliferation rates in culture as
many of these lines are extremely slow growing (Table 2), but may
instead be a reflection of the well-documented inoculum effect
whereby VCR cytotoxicity is increased at lower cell densities
(Kobayashi et al, 1998). Alternatively, adaptation to an in vitro
microenvironment may mitigate changes to cell architecture that
render the cell more sensitive to the microtubule-blocking effects
of VCR.
PER-145 was found to be highly resistant to MTX and had
relatively high IC50 values for all of the drugs, except ASP for which
it appears to have retained sensitivity (Table 2). This cell line has a
complex karyotype (Table 1) and was derived from a patient who
had received escalating doses of MTX (as per the Capizzi I
schedule) in the 5 weeks immediately before his third relapse; the
cell line was isolated from this third relapse specimen and has
presumably undergone selection for MTX resistance in vivo. The
patient subsequently relapsed for a fourth time after having
received high-dose ARA-C; a description of an additional cell line
isolated from this later time point and demonstrating resistance
to ARA-C has previously been published (Kees, 1987; Kees et al,
1989a). The retention of ASP sensitivity in PER-145 may be related
to the fact that this cell line carries the TEL-AML1 translocation
(Kees et al, 2003), which has been linked to increased ASP
sensitivity in ALL (Ramakers-van Woerden et al, 2000). Closer
examination of the mechanism for MTX resistance in this cell line
is currently underway.
In T-ALL cell lines, there was significant IC50 correlation
between DNR, DOX, VCR and ARA-C, consistent with previous
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Figure 3 Resistance profiles of MPRED, DEX, ASP and MTX in T-ALL cell lines. Delta IC50 scores (Log2 IC50 – median Log2 IC50) were calculated for
each drug and cell lines plotted from left to right according to their Delta IC50 rank for MPRED.
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sstudies indicating mechanisms of cross-resistance for these drugs
(Kaspers et al, 1998; Martin-Aragon et al, 2000; Lofgren et al,
2004). We found a positive correlation between glucocorticoid and
ASP resistance, indicating that sensitivity to these unrelated
compounds may also be influenced by common biological factors,
possibly through alterations in apoptosis (Holleman et al, 2003).
There was no correlation between the glucocorticoids and
thiopurines, but between glucocorticoids and MTX there was in
fact evidence of an inverse relationship. Lack of cross-resistance
between MTX and glucocorticoids has previously been highlighted
by a small study in ALL patient specimens (Hegge et al, 1999) but,
to the best of our knowledge, a directly inverse relationship as
indicated by the present data has not yet been described. It is
interesting to speculate that this phenomenon may relate to
differential expression of specific multidrug transporters, for
example the coordinated upregulation of ABCG2 (breast cancer
resistance protein or BCRP) and downregulation of ABCC1
(MRP1); such changes have recently been associated with reciprocal
changes in the sensitivities to DEX and MTX in CEM cells (1.8-fold
increase in resistance to MTX, and a 13-fold decrease in resistance
to DEX (van der Heijden et al, 2004)). The ratio of these same drug
transporters is also important for MTX pharmacodynamics in
paediatric ALL (Kager et al, 2005). ABCG2 is a major transporter
for MTX that can be directly inhibited by DEX and MPRED, but
apparently not by prednisolone (Pavek et al, 2005). In the present
study, MTX resistance was also negatively correlated with ASP
resistance. The data therefore suggest that for patients who show
resistance to glucocorticoids and ASP (e.g. at relapse), treatment
with MTX may be increasingly relevant. Further work is required to
confirm the observed reciprocity between these drugs but, if
genuine, the finding has direct implications for the clinical setting
and the design of protocols for relapsing patients.
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